CombiGene
3.77 SEK +0.27%Be the first to follow this company
CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.
Revenue
5.54M
EBIT %
-696.75 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
COMBI
Daily low / high price
3.76 / 3.87
SEK
Market cap
74.65M SEK
Turnover
20.36K SEK
Volume
5.3K
Financial calendar
Interim report
17.05.2024
General meeting
23.05.2024
Interim report
23.08.2024
Interim report
08.11.2024
Annual report
14.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Jan Ivar Nordqvist | 9.4 % | 9.4 % |
Pareto Securities | 5.6 % | 5.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Notice of Annual General Meeting in CombiGene AB (publ)
BioStock: CombiGene's CEO comments on the patent approvals in Australia and India
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools